Biotech · Private company
USWM CT, LLC
Track this companyFree. Adds USWM CT, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials96 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- Afamitresgene autoleucelPhase 2 · Synovial SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- afamitresgene autoleucel (previously ADP-A2M4)Phase 2 · Synovial SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- Autologous genetically modified ADP-A2M4CD8 cellsPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Autologous genetically modified ADP-A2M4CD8 cells in combination with NivolumabPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 2 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 2 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Letetresgene autoleucel (lete-cel, GSK3377794)Phase 2 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- ADP adoptive cell therapyPhase 1 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeksPhase 1 · Endometrial CancerClinicalTrials.gov · fetched Nov 12, 2026
- Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiationPhase 1 · Urinary Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cellsPhase 1 · Urinary Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- Non-conforming afamitresgene autoleucelSynovial SarcomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- SPEARHEAD-3 Pediatric StudyPHASE1_PHASE2 · RECRUITING · started Sep 1, 2023ClinicalTrials.gov NCT05642455 · fetched Nov 12, 2026
- ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)PHASE2 · TERMINATED · started Jun 26, 2023ClinicalTrials.gov NCT05601752 · fetched Nov 12, 2026
- Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell LiposarcomaPHASE2 · COMPLETED · started Dec 31, 2019ClinicalTrials.gov NCT06703346 · fetched Nov 12, 2026
- Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid TumorsPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 31, 2019ClinicalTrials.gov NCT03967223 · fetched Nov 12, 2026
- ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)PHASE1 · ACTIVE_NOT_RECRUITING · started Aug 20, 2019ClinicalTrials.gov NCT04044859 · fetched Nov 12, 2026
- Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 13, 2019ClinicalTrials.gov NCT04044768 · fetched Nov 12, 2026
- Adoptive Cell Therapy Long-term Follow-up (LTFU) StudyPHASE1 · ENROLLING_BY_INVITATION · started Apr 9, 2018ClinicalTrials.gov NCT03391778 · fetched Nov 12, 2026
- MAGE-A4ᶜ¹º³²T for Multi-TumorPHASE1 · ACTIVE_NOT_RECRUITING · started May 15, 2017ClinicalTrials.gov NCT03132922 · fetched Nov 12, 2026
- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-celAVAILABLEClinicalTrials.gov NCT06617572 · fetched Nov 12, 2026